Trending Now
All For One Media (AFOM) in Focus as the Drama Drama...
Investment capital has been flowing toward entertainment stocks as part of a broad reopening trade that has swept up family fun centers,...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
The Crypto Dip is a Fresh Shot at Exposure to the...
Crypto is dead. Long live crypto.
This market, perhaps above all others, is the ultimate roller coaster. Crypto investors...
MAKE IT MODERN
LATEST REVIEWS
Inovio Pharmaceuticals Inc. (NASDAQ:INO) Signs Deal With Kaneka Eurogentec For Manufacture...
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has entered a manufacturing deal with Japan's Kaneka Corp to manufacture its COVID-19 vaccine candidate. The US vaccine maker didn't...
MAKE IT MODERN
PERFORMANCE TRAINING
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reveals 18-month data From Its Phase 1b APL2-103 study
Apellis Pharmaceuticals Inc (NASDAQ:APLS) recently 18 months’ worth of data collected through its Phase 1b APL2-103 study evaluating pegcetacoplan as a treatment for advanced...
Cellect Biotechnology Ltd – ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for...
Every successful medicinal activity requires mass production of quality stem cells. This is what avails regenerative medicine to the public the need occasioned the...
Viking Therapeutics (VKTX): Is This Weight Loss Drug Contender Worth Buying on the Dip?
Viking Therapeutics (NASDAQ: VKTX) has made significant waves in the biotechnology sector this year, emerging as a formidable contender in the booming...
Can-Fite (NYSEAMERICAN:CANF) Submits Investigational New Drug for a Phase II Study of Piclidenoson in...
Can-Fite (NYSEAMERICAN:CANF) has been using its capabilities to develop an innovative pipeline of patented compounds aimed at treating autoimmune-inflammatory and liver diseases. However, with...
Clovis Oncology Inc. (NASDAQ:CLVS) Reports Q3 2020 Results With Rubraca Sales Of $38.8 Million
Clovis Oncology Inc. (NASDAQ:CLVS) has announced results for Q3 2020 and also offers an update on its clinical development programs and commercial outlook for...
MAKE IT MODERN
